| Bioactivity | USL311 is a potent and selective CXCR4 antagonist, with anti-tumor activity. USL311 prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4[1]. | ||||||||||||
| Name | USL311 | ||||||||||||
| CAS | 1373268-67-7 | ||||||||||||
| Formula | C24H34N6O | ||||||||||||
| Molar Mass | 422.57 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Peter Richardson. Usl-311 for use in the treatment of cancer. WO2018162924A1 [2]. Takacs GP, et al. Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy. Pharmacol Ther. 2021 Jun;222:107790. |
USL311
CAS: 1373268-67-7 F: C24H34N6O W: 422.57
USL311 is a potent and selective CXCR4 antagonist, with anti-tumor activity. USL311 prevents the binding of stromal-cell
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.